Screener
MBX Biosciences, Inc. MBX Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by MBX Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: MBX Biosciences, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 9:03 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210593
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Accrued expenses | (4,857) | 558 |
| Other assets | (43) | — |
| Operating lease liability | (41) | (42) |
| Net cash used in operating activities | (20,208) | (22,678) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (437) | (30) |
| Purchases of marketable securities | (154,160) | (58,894) |
| Maturities of marketable securities | 57,500 | 57,150 |
Item 1. Financial Statements.
FAQ
- What is MBX Biosciences, Inc.'s operating cash flow?
- MBX Biosciences, Inc. (MBX) reported operating cash flow of -$20.21M in Q1 2026.
- How has MBX Biosciences, Inc.'s operating cash flow changed year-over-year?
- MBX Biosciences, Inc.'s operating cash flow increased by 10.9% year-over-year, from -$22.68M to -$20.21M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about MBX Biosciences, Inc.'s operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude